key: cord-0683785-p17lvvua
authors: Schousboe, Peter; Wiese, Lothar; Heiring, Christian; Verder, Henrik; Poorisrisak, Porntiva; Verder, Povl; Nielsen, Henning Bay
title: Assessment of pulmonary surfactant in COVID-19 patients
date: 2020-09-07
journal: Crit Care
DOI: 10.1186/s13054-020-03268-9
sha: 6092d11135344760af1bdb2d159b4429d4fda0fd
doc_id: 683785
cord_uid: p17lvvua

nan

The clinical presentation of coronavirus 2 (SARS-CoV-2) ranges from asymptomatic to severe respiratory failure, and correspondingly requirement for respiratory support ranging from varying levels of supplementary O 2 , to non-invasive and invasive ventilation. In a recent editorial by Gattinoni et al. [1] , it is proposed that, based on different pathophysiology need for ventilator support, there are two groups of COVID-19 patients: one group that develops acute respiratory distress syndrome (ARDS) with low compliance, and another classified as non-ARDS with normal compliance and hypoxemia caused by a high level of intrapulmonary shunting. Furthermore, non-ARDS type COVID-19 pneumonia may transit to ARDS-type COVID-19 by self-inflicted or ventilator-induced lung injury.

We propose that the direct effects on pulmonary tissue by SARS-CoV-2 in COVID-19 pneumonia in ARDS COVID-19 patients resembles neonatal respiratory distress syndrome (NRDS), caused by surfactant deficiency.

SARS-CoV-2 enters and replicates in the alveolar type II cells impacting the production and turnover of pulmonary surfactants. This results in alveolar collapse and inflammation leading to increased capillary permeability, edema, and microvascular thrombosis; where the associated ARDS clinical picture closely resembles NRDS. Of importance, as ARDS progresses, vascular permeability increases and surfactant deactivates making the lung increasingly unstable [2] . Thus, clinical studies have provided promising data on the effect of surfactant treatment in patients with ARDS [3] . These pathophysiological findings have prompted several groups to investigate if surfactant administration could improve the COVID-19 patient outcome. Interventional trials are currently underway in the UK, USA, and Canada (ClinicalTrials.gov IDs: NCT04375735, NCT04362059, NCT04384731).

Treatment of NRDS with rescue surfactant and continuous positive airway pressure (CPAP), when compared to mechanical ventilation, results in reduced development of pulmonary fibrosis; a complication also reported in intubated COVID-19 patients. Antenatal corticosteroid treatment may also accelerate fetal lung maturation in the risk of preterm birth. A multicentre trial evaluates whether surfactant plus budesonide improves survival in NRDS [4] . In COVID-19 patients, dexamethasone seems to improve the outcome.

We suggest assessment of surfactant levels should be added to the evaluation of COVID-19 patients. A pointof-care test for fast measuring surfactant at birth in premature babies has been developed [5] . This method may be suitable for determining the surfactant in tracheal fluid obtained from critically ill adults. Knowledge of surfactant levels contributes to understanding pathophysiology in COVID-19 patients. Surfactant treatment may be considered included with other interventions for the treatment of COVID-19 induced respiratory failure.

COVID-19 pneumonia: ARDS or not?

Acute lung injury: how to stabilize a broken lung

Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis

Multicentre randomised controlled trial of surfactant plus budesonide to improve survival free of bronchopulmonary dysplasia in extremely preterm infants PLUSS trial

Predicting respiratory distress syndrome at birth using a fast test based on spectroscopy of gastric aspirates: 2. Clinical part

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

Morgaine Matthews is acknowledged for proofreading.

The authors all contributed with inputs to the manuscript derived from observations of COVID-19 patients in the ICU and experiences from ongoing